Proteomic and Metabolomic Features Testing for Immunotherapy Response in Non-Small Cell Lung Cancer
The objective of this study is to use blood and urine proteomic and metabolomic features to monitor lung cancer immunotherapy response.
• Patients who are 18 years or older at the time of signing the informed consent form;
• Patients with histologically or cytologically confirmed non-small cell lung cancer that is metastatic or locally advanced unresectable, not eligible for local curative treatment (Stage IIIB or IV according to AJCC);
• Patients without contraindications for immunotherapy according to CSCO guidelines for Non-Small Cell Lung Cancer (NSCLC) version 2022（No EGFR mutations, ALK or ROS1 rearrangement);
• Patients with at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors \[RECIST\], version 1.1;
• Patients who have not received systemic treatment in the past, or who have previously received (neo) adjuvant treatment/radical treatment programs and have relapsed for more than 6 months;
• Patients who signed the informed consent and are willing to participate in the study.